Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Genomic Advances Pave the Way for New Therapies in AML

March 1st 2017

In an OncLive Peer Exchange® panel, experts discussed novel cytotoxic and targeted agents in the pipeline that are likely to provide new options for treating certain individuals with acute myeloid leukemia.

Axicabtagene Ciloleucel Shows High CR Rates in Primary Analysis of ZUMA-1 Study

February 28th 2017

Treatment with axicabtagene ciloleucel demonstrated an objective response rate of 82% and a complete response rate of 54% for patients with aggressive non-Hodgkin lymphoma.

Dr. Garfall on CAR T Cells in ALL

February 28th 2017

Alfred L. Garfall, MD, MS, assistant professor of Medicine at the Hospital of the University of Pennsylvania, discusses CAR T-cells in acute lymphoblastic leukemia (ALL).

Dr. Fanale on Clinical Trials for T-Cell Lymphoma

February 28th 2017

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.

Axicabtagene Ciloleucel Shows Response Rate of 76% in Aggressive Lymphoma

February 27th 2017

Axicabtagene ciloleucel had an objective response rate of 76% and a complete response rate of 47% in patients with aggressive non-Hodgkin lymphoma followed for at least 1 month.

Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma

February 26th 2017

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Dr. Scott on Conditioning Regimens for Stem Cell Transplants

February 26th 2017

Bart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.

Researchers Examine Acquired Mutations Linked to Ibrutinib Resistance in CLL

February 25th 2017

Researchers hope the acquired ibrutinib resistance mutations BTK and PLCG2 can be used as biomarkers for early intervention opportunities in patients with chronic lymphocytic leukemia.

Vaccine Limits Herpes Zoster Infections Following Stem Cell Transplant

February 25th 2017

Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.

Outcomes Have Improved Over Time in Myeloma Patients Relapsing Early After ASCT

February 25th 2017

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults With AML

February 25th 2017

Dr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.

Dr. Kebriaei on the Iomab-B Clinical Trial

February 25th 2017

Partow Kebriaei, MD, discusses the Iomab-B clinical trial for older patients with acute myeloid leukemia.

Dr. Mesa on Incorporating MPN Guidelines into Clinical Practice

February 25th 2017

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses how community oncologists can incorporate the NCCN Guideline for Myeloproliferative Neoplasms (MPNs) into clinical practice.

Dr. Burke on Findings of GOYA Study for Diffuse Large B-Cell Lymphoma

February 24th 2017

John M. Burke, MD, Rocky Mountain Cancer Centers, discusses the significant findings of the phase III GOYA study investigating obinutuzumab (Gazyva) plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Biomarker-Driven Study Aims for Genomic Breakthroughs in AML

February 24th 2017

A wide-ranging clinical trial is investigating a novel method of determining treatment regimens for acute myeloid leukemia based on genomic testing for each individual patient.

EC Approves Maintenance Lenalidomide for Myeloma

February 24th 2017

The European Commission has expanded the indication for lenalidomide (Revlimid) to include use as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

Goy Shares Expertise on Exciting Progress in MCL

February 24th 2017

Andre Goy, MD, discusses combination regimens and other developments in the evolving treatment landscape in mantle cell lymphoma.

CPX-351 Offers Potential Bridge to Transplant for Secondary AML

February 23rd 2017

More patients with acute myeloid leukemia could proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen.

FDA Grants Inotuzumab Ozogamicin Priority Review for ALL

February 22nd 2017

The FDA has granted a priority review designation to inotuzumab ozogamicin for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.

Dr. Herrera on Next Steps of Drug Combinations for Hodgkin Lymphoma

February 17th 2017

Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses next steps for a phase I/II study of brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) in patients with relapsed or refractory Hodgkin lymphoma.